Lausanne, September 27, 2018 – SOPHiA GENETICS has received yesterday evening at the Convergence in Oncology Summit (Biopôle – Lausanne), the “Salus Partner Excellence in HealthTech Award”. This prize recognizes the company’s progress in the democratization of Data-Driven Medicine.
SOPHiA GENETICS is a health tech company that has developed SOPHiA AI, the most advanced and used technology for Data-Driven Medicine. SOPHiA helps clinicians better diagnose, treat and monitor patients thanks to accurate and standardized clinical genomics analysis. SOPHiA supports the diagnosis of 1 patient every 5 minutes, +250’000 to date.
Upon receiving the award Dr Jurgi Camblong CEO and co-founder of SOPHiA GENETICS comments: “In the context of Convergence in Oncology, our mission is to allow and encourage knowledge sharing, key to deliver disruptive solutions in the fight against cancer. We are very happy and honored to receive the 2018 Salus Excellence in HealthTech Award. It is again the recognition of our teamwork dedicated to help as many patients as possible worldwide.”
“SOPHiA GENETICS joins a prestigious group of companies recognized by the Salus Partners Excellence in Health Tech Award. They are a great example of the flourishing innovation in Health Tech in Switzerland.” says Dr. Brian Hashemi, Co-Organizer of the Convergence in Oncology Summit and Managing Partner of the investment firm Salus Partners.
Previous winners of the award have been experiencing great momentum: Endosense – a Geneva-based company in cardiac ablation, acquired by St. Jude for CHF300mm. Sapiens – innovation in Deep Brain Stimulation, acquired by Medtronic for USD200mm. Molecular Partners – a Zurich-based Biotech introducing DARPins as a new class of biologicals in ophthalmology and cancer, now on the Swiss Stock Exchange with a market cap of CHF470mm.
The Convergence in Oncology Summit
The Convergence in Oncology Summit held in Lausanne, Switzerland is an international annual assembly of industry leaders, entrepreneurs, and investors active in the field of Oncology to explore synergies that can accelerate the development of the most promising solutions to fight cancer. The annual event is attended by CEOs, entrepreneurs, investors, and thought leaders from both academia and industry to discuss and debate the key issues of global concern in Oncology.